Background:Atypical pneumonia is caused by the SARS CoV-2 virus in persons who have it. Inflammation is induced by the virus, which aids viral reproduction, dissemination, tissue injury, and hypoxia. Bevacizumab is a prominent anti-VEGF monoclonal antibody that has been approved by the USFDA for colorectal carcinoma, non-small cell lung carcinoma, renal carcinoma, recurrent glioblastoma, cervical carcinoma, and ovarian carcinoma. We conducted this study to look into the clinical benefits of bevacizumab in combination with standard care for patients with moderate to severe COVID-19 disease.